Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Thymalfasin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : SciClone Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 30, 2023
Lead Product(s) : Thymalfasin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : SciClone Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thymalfasin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Davita Clinical Research | Clinical Research Consultants, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 11, 2020
Lead Product(s) : Thymalfasin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Davita Clinical Research | Clinical Research Consultants, LLC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thymalfasin
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 19, 2016
Lead Product(s) : Thymalfasin
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thymalfasin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 19, 2016
Lead Product(s) : Thymalfasin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thymalfasin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : SciClone Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
The Efficacy and Safety of Ta1 for Sepsis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 15, 2016
Lead Product(s) : Thymalfasin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : SciClone Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thymalfasin
Therapeutic Area : Oncology
Study Phase : Phase IV
Sponsor : SciClone Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 02, 2014
Lead Product(s) : Thymalfasin
Therapeutic Area : Oncology
Highest Development Status : Phase IV
Sponsor : SciClone Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Thymalfasin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : SciClone Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 10, 2010
Lead Product(s) : Thymalfasin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : SciClone Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable